



Claims:

1. A crystalline compound having the structure of formula (I),



2. The crystalline compound of claim 1, wherein the compound is anhydrous.
3. The crystalline compound of claim 2, having 2θ values 20.03; 20.14; 21.83; and 25.73.
4. The crystalline compound of claim 3, having 2θ values 20.03; 20.14; 21.03; 21.83; 23.08; 23.39; 25.73; and 26.59.
5. The crystalline compound of claim 4, having 2θ values 7.70; 11.54; 12.64; 16.03; 18.99; 20.03; 20.14; 20.83; 21.03; 21.83; 23.08; 23.39; 25.48; 25.73; 26.59; and 29.78.
6. The crystalline compound of claim 5, having 2θ values 7.70; 9.95; 11.54; 12.64; 16.03; 18.18; 18.99; 19.16; 19.44; 20.03; 20.14; 20.83; 21.03; 21.83; 22.44; 23.08; 23.39; 23.89; 24.08; 24.53; 24.68; 25.05; 25.48; 25.73; 26.08; 26.59; 27.33; 27.67; 29.78; and 29.92.
7. The crystalline compound of claim 6, having an XRD pattern substantially as shown in FIG. 1, labeled Form 1.
8. The crystalline compound of claim 1, wherein the compound is a dimethylsulfoxide solvate.
9. The crystalline compound of claim 8, having 2θ values 8.29; 17.39; 19.54; 22.78; and 22.98.
10. The crystalline compound of claim 9, having 2θ values 8.29; 17.39; 19.54; 19.74; 20.98; 21.58; 22.03; 22.78; 22.98; and 25.53.

11. The crystalline compound of claim 10, having 2 θ values 8.29; 16.10; 17.39; 19.24; 19.54; 19.74; 20.33; 20.78; 20.98; 21.18; 21.58; 22.03; 22.78; 22.98; 25.53; 28.48; and 29.48.
12. The crystalline compound of claim 11, having 2 θ values 8.29; 13.12; 15.79; 16.10; 16.69; 17.39; 19.03; 19.24; 19.54; 19.74; 20.33; 20.78; 20.98; 21.18; 21.58; 22.03; 22.78; 22.98; 23.95; 24.14; 24.48; 24.64; 25.14; 25.53; 25.87; 26.89; 27.18; 27.67; 28.02; 28.13; 28.48; 28.98; 29.34; 29.48; and 29.92.
13. The crystalline salt of claim 12, having an XRD pattern substantially as shown in FIG. 1, labeled Form 2.
14. A pharmaceutical composition comprising the salt of any one of claims 1-13 and one or more pharmaceutically acceptable excipients.
15. A method for preparing a crystalline compound having the structure of formula (I):



comprising:

- a) providing a mixture of a compound of formula (I) in a solvent; and
- b) crystallizing the compound of formula (I) from the mixture comprising the compound of formula (I).
16. The method of claim 15, wherein the crystalline compound is anhydrous.
17. The method of claim 15, wherein the crystalline compound is a solvate.
18. The method of claim 17, wherein the solvate is a dimethylsulfoxide solvate.
19. The method of claim 15, wherein the solvent is methanol or water.
20. The method of claim 18, wherein the solvent is dimethylsulfoxide.
21. The method of any one of claims 15-20, wherein the mixture comprising the compound of formula (I) is a solution, and the step of crystallizing the compound of formula

(I) from the mixture comprises bringing the solution to supersaturation to cause the compound of formula (I) to precipitate out of solution.

22. The method of claim 21, wherein the step of bringing the solution to supersaturation comprises slowly adding an anti-solvent, allowing the solution to cool, reducing the volume of the solution, or any combination thereof.

23. The method of claim 21, wherein the step of bringing the solution to supersaturation comprises cooling the solution to ambient temperature or lower.

24. The method of any one of claims 15-20, wherein the mixture comprising the compound of formula (I) is a slurry.

25. The method of any one of claims 15-24, further comprising isolating the crystalline compound.

26. The method of claim 25, wherein isolating the crystalline compound comprises filtering the crystallized compound from the mixture.

27. The method of claim 25 or claim 26, further comprising drying the crystalline compound under reduced pressure.

28. The method of any one of claims 15-27, wherein the crystalline compound is the crystalline compound of any one of claims 1-13.